1. The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer
   Qiang Chen et al, 2016, Medicine CrossRef
2. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
   Olivier Bouché et al, 2019, World Journal of Gastroenterology CrossRef
3. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
   Jesús García-Foncillas et al, 2019, Frontiers in Oncology CrossRef
4. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
   T. Yoshino et al, 2018, Annals of Oncology CrossRef
5. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
   Yanhong Yao et al, 2021, Frontiers in Pharmacology CrossRef
6. Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
   Sander Ketzer et al, 2018, Clinical Pharmacokinetics CrossRef
7. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
   Elena Elez et al, 2019, British Journal of Cancer CrossRef